Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9568775 | 0.89 | NPSR1 (0.50) | MAPK1ALDH1A1HPGD | |
| SCHEMBL8947063 | 0.86 | ALDH1A1 (0.46) | ALDH1A1HPGDHSD11B1 | |
| SCHEMBL8947316 | 0.82 | ALDH1A1 (0.63) | ALDH1A1HPGDHSD11B1 | |
| SCHEMBL8947288 | 0.82 | — | — | |
| SCHEMBL9568853 | 0.81 | ALDH1A1 (0.65) | MAPK1ALDH1A1HPGDHSD11B1 | |
| SCHEMBL9568925 | 0.81 | ALDH1A1 (0.54) | MAPK1ALDH1A1HPGDHSD11B1 | |
| SCHEMBL8947078 | 0.78 | ALDH1A1 (0.60) | ALDH1A1HPGDHSD11B1 | |
| SCHEMBL8947125 | 0.77 | L3MBTL1 (0.48) | MAPK1ALDH1A1HPGDHSD11B1 | |
| SCHEMBL9568758 | 0.75 | ALDH1A1 (0.41) | MAPK1ALDH1A1HPGDHSD11B1 | |
| SCHEMBL8947156 | 0.74 | MAPK1 (0.60) | MAPK1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5262433-A | Antidiabetic agents | WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) | 1993-11-16 | — | — | US | disclosed |
| EP-0528277-A1 | Tetrazoleacetic acid derivatives aldose reductase inhibitors | Wakamoto Pharmaceutical Co., Ltd. (JP) | 1993-02-24 | — | — | EP | disclosed |